ATR and acute myeloid leukemia: In data from the DepMap project97, the loss of TLK2 reduced the fitness of the majority of cancer cell lines tested, similar to ATR, and TLK2 deletion in mouse models of AML markedly impaired cancer growth, indicating that TLK inhibition will likely have broader anti-cancer effects that are not limited to ALT-positive cells98.